Home LiteratureArticle Details
PMID: 8001022 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model.

Cancer immunology, immunotherapy : CII ·Vol. 39 ·No. 6 ·1994-12-00 ·Pages 347-59

Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Himbeck RP, Davis MR, Manning LS, Robinson BW

Abstract

Malignant mesothelioma (MM) is an aggressive, uniformly fatal serosal tumour, usually associated with asbestos exposure, for which there currently is no effective treatment. In order to gain insight into the mechanism(s) whereby MM might escape immune surveillance, a murine model for MM was used (a) to characterise the tumour-infiltrating lymphocytes (TIL) and macrophages (TIM) phenotypically, (b) to examine systemic immune recognition of MM, and (c) to examine the possible influence of tumour-derived cytokines on systemic and local pathobiological manifestations of MM. A profound down-regulation of lymphocyte surface markers, known to be involved in T cell activation, was found in TIL. Likewise, although TIM were present in large numbers, their expression of MHC class II antigen and integrins was weak or absent, suggestive of altered functional activity. Significant amounts of cytokines, in particular transforming growth factor beta, interleukin-6 (IL-6), IL-1 and tumour necrosis factor were produced during the course of MM tumour development-directly by the MM cells and/or indirectly in response to tumour growth. These factors may contribute both to derangement of antitumour effector mechanisms and to the clinical and pathological manifestations of the disease.

MeSH Terms
Animals Antigens, CD/analysis Cytokines/biosynthesis Female Immunophenotyping Lymphocytes, Tumor-Infiltrating/immunology Macrophages/pathology Mesothelioma/immunology,pathology Mice Mice, Inbred BALB C Mice, Inbred CBA Transforming Growth Factor beta/physiology
Chemicals
Antigens, CD Cytokines Transforming Growth Factor beta
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Bielefeldt-Ohmann H
University of Western Australia Department of Medicine, QEII Medical Centre, Nedlands.
Fitzpatrick D R
Marzo A L
Jarnicki A G
Himbeck R P
Davis M R
Manning L S
Robinson B W
References (44)
44 references, click to expand
  1. The CD3-gamma and CD3-delta subunits of the T cell antigen receptor can be expressed within distinct functional TCR/CD3 complexes.
    EMBO J. 1991 Apr;10(4):903-12 PMID: 1826255
  2. Preferential binding of Chlamydia trachomatis to subsets of human lymphocytes and induction of interleukin-6 and interferon-gamma.
    Immunol Cell Biol. 1991 Oct;69 ( Pt 5):337-48 PMID: 1787004
  3. Characterization of a monoclonal antibody directed against the murine B lymphocyte receptor for IgE.
    J Immunol. 1987 Mar 15;138(6):1845-51 PMID: 2950171
  4. Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes.
    J Immunol. 1993 Apr 1;150(7):2972-80 PMID: 8095957
  5. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.
    Proc Natl Acad Sci U S A. 1987 Aug;84(16):5788-92 PMID: 2886992
  6. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma.
    Growth Factors. 1994;11(1):29-44 PMID: 7833058
  7. Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay.
    J Immunol. 1990 Nov 1;145(9):2938-45 PMID: 2145365
  8. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.
    Proc Natl Acad Sci U S A. 1991 May 1;88(9):3535-9 PMID: 2023898
  9. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality.
    Chest. 1993 Feb;103(2):565-75 PMID: 8432155
  10. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.
    J Exp Med. 1987 Nov 1;166(5):1229-44 PMID: 2960769
  11. Signaling for death of lymphoid cells.
    Curr Opin Immunol. 1993 Jun;5(3):368-73 PMID: 7688515
  12. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.
    J Immunol. 1991 Feb 1;146(3):1077-82 PMID: 1671050
  13. Role of CD3 delta in surface expression of the TCR/CD3 complex and in activation for killing analyzed with a CD3 delta-negative cytotoxic T lymphocyte variant.
    J Immunol. 1992 Feb 1;148(3):657-64 PMID: 1530953
  14. Effect of interferon-alpha 2a on malignant mesothelioma.
    J Interferon Res. 1993 Feb;13(1):9-12 PMID: 8454913
  15. Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming growth factor-beta.
    Eur J Immunol. 1992 Apr;22(4):1031-6 PMID: 1551403
  16. Establishment of a murine model of malignant mesothelioma.
    Int J Cancer. 1992 Dec 2;52(6):881-6 PMID: 1459729
  17. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines.
    J Immunol Methods. 1984 May 25;70(2):257-68 PMID: 6609997
  18. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor.
    J Immunol. 1993 Mar 15;150(6):2341-5 PMID: 8450216
  19. Bovine alveolar macrophages: phenotypic and functional properties of subpopulations obtained by Percoll density gradient centrifugation.
    J Leukoc Biol. 1986 Feb;39(2):167-81 PMID: 3001213
  20. CD3-gamma, -delta, -epsilon, -zeta, T-cell receptor-alpha and -beta transcripts are independently regulated during thymocyte ontogeny and T-cell activation.
    Immunology. 1992 Nov;77(3):465-8 PMID: 1478692
  21. Double-immunolabeling systems for phenotyping of immune cells harboring bovine viral diarrhea virus.
    J Histochem Cytochem. 1987 Jun;35(6):627-33 PMID: 3033062
  22. Human tumor-infiltrating lymphocytes: a marker of host response.
    Semin Hematol. 1985 Jan;22(1):27-40 PMID: 3155876
  23. Mononuclear cells infiltrating human mammary carcinomas: immunohistochemical analysis with monoclonal antibodies.
    Int J Cancer. 1985 Jun 15;35(6):753-62 PMID: 2989190
  24. Differential effect of transforming growth factor beta on the synthesis of Th1- and Th2-like lymphokines by human T lymphocytes.
    Eur J Immunol. 1992 Aug;22(8):2173-6 PMID: 1386318
  25. An immunohistological study of cells infiltrating progressive and regressive tumors induced by two variant subpopulations of a rat colon cancer cell line.
    Int J Cancer. 1987 Jul 15;40(1):87-93 PMID: 3298078
  26. Identification of a monoclonal antibody specific for a murine T3 polypeptide.
    Proc Natl Acad Sci U S A. 1987 Mar;84(5):1374-8 PMID: 2950524
  27. Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells.
    J Exp Med. 1983 Sep 1;158(3):836-56 PMID: 6193236
  28. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia.
    J Immunol. 1992 Jun 1;148(11):3674-8 PMID: 1534101
  29. Heterogeneity of lymphocyte homing physiology: several mechanisms operate in the control of migration to lymphoid and non-lymphoid organs in vivo.
    Immunol Rev. 1989 Apr;108:83-109 PMID: 2670746
  30. Frequency analysis of lymphokine-secreting CD4+ and CD8+ T cells activated in a graft-versus-host reaction.
    J Immunol. 1990 Oct 1;145(7):2167-76 PMID: 1975827
  31. Modulation of monocyte type I transforming growth factor-beta receptors by inflammatory stimuli.
    J Biol Chem. 1991 Oct 15;266(29):19697-703 PMID: 1655792
  32. The biologic roles of CD2, CD4, and CD8 in T-cell activation.
    Annu Rev Immunol. 1989;7:579-99 PMID: 2653377
  33. Transforming growth factor-beta 1 inhibits murine immediate and delayed type hypersensitivity.
    J Immunol. 1992 Jul 15;149(2):521-8 PMID: 1624798
  34. Differential activation of antigen-stimulated suicide and cytokine production pathways in CD4+ T cells is regulated by the antigen-presenting cell.
    J Immunol. 1993 May 1;150(9):3832-42 PMID: 7682585
  35. Discussion paper: are peripheral and in situ tumor immunity related?
    Ann N Y Acad Sci. 1976;276:373-80 PMID: 1071967
  36. Modulation of cytokine production by transforming growth factor-beta.
    J Immunol. 1989 Jun 15;142(12):4295-300 PMID: 2542408
  37. Tolerance of T-cell clones is associated with membrane antigen changes.
    Nature. 1983 Jun 16-22;303(5918):625-7 PMID: 6343888
  38. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice.
    Science. 1992 Dec 11;258(5089):1795-8 PMID: 1465616
  39. Haemorrhage-induced alterations in function and cytokine production of T cells and T cell subpopulations.
    Clin Exp Immunol. 1992 Dec;90(3):497-502 PMID: 1360880
  40. Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice.
    Cancer Res. 1991 Jul 1;51(13):3590-4 PMID: 2054795
  41. Responsiveness of the interleukin (IL)-6-dependent cell line B9 to IL-11.
    J Immunol Methods. 1993 Jan 14;158(1):147-8 PMID: 8429212
  42. Tumor modulation of autoreactivity: decreased macrophage and autoreactive T cell interactions.
    Cell Immunol. 1990 Apr 15;127(1):105-19 PMID: 2138515
  43. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor.
    J Exp Med. 1990 Sep 1;172(3):997-1000 PMID: 2388041
  44. Monoclonal antibodies specific for murine CD2 reveal its presence on B as well as T cells.
    Proc Natl Acad Sci U S A. 1989 Jan;86(2):645-9 PMID: 2463634
Article Info
Journal
Cancer immunology, immunotherapy : CII
Abbr.
Cancer Immunol Immunother
ISSN
0340-7004
Published
1994-12-00
Pages
347-59
Language
English
Region
Germany
NLM ID
8605732
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com